Meghna Muralidhar
About Meghna Muralidhar
Meghna Muralidhar is a scientist with extensive experience in biotechnology, currently working at Stridebio, Inc in Durham, North Carolina. She has held various research and development roles at notable organizations including Genentech, Novartis, and Medimmune, and has a Master's degree from Texas A&M University.
Work at StrideBio
Meghna Muralidhar has been employed at Stridebio, Inc as a Scientist since 2017. Her role in the company is based in Durham, North Carolina, where she has contributed to various scientific projects over the past seven years. Stridebio focuses on developing innovative gene therapies, and Muralidhar's expertise plays a significant role in advancing the company's research objectives.
Previous Experience in Biotechnology
Prior to her current position, Muralidhar held several roles in the biotechnology sector. She worked as a Development Engineer II at Novartis for seven months in Basel, Switzerland, in 2014. Before that, she served as an R&D Associate II at Medimmune for ten months in Gaithersburg, Maryland, from 2013 to 2014. Her experience also includes a role as a Research Associate at Genentech in South San Francisco from 2012 to 2013.
Education and Expertise
Meghna Muralidhar earned her Master's degree in Biotechnology from Texas A&M University, where she studied from 2010 to 2012. She also holds a Bachelor of Engineering in Biotechnology from R. V. College of Engineering in Bangalore, which she completed from 2006 to 2010. Her educational background provides a strong foundation for her work in the biotechnology field.
Early Career and Internships
Muralidhar began her career with various internships and trainee positions. In 2009, she worked as a Trainee at The Jain Group of Institutions for one month. She also served as a Lab Research Assistant at Texas A&M Health Science Center from 2010 to 2011 and as a Research Intern at Texas A&M University for two months in 2011. Additionally, she worked as a Graduate Research Assistant at Texas A&M University from 2011 to 2012.